Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Sponsor: Graceway Pharmaceuticals, LLC
Terminated
Unable to reach target enrollment of 60 subjects
Other terminated trials from Graceway Pharmaceuticals, LLC
More terminations from Graceway Pharmaceuticals, LLC
Other Actinic Keratosis trials with similar outcome
Listed as NCT01203878, this PHASE4 trial focuses on Actinic Keratosis and remains terminated or withdrawn. Sponsored by Graceway Pharmaceuticals, LLC, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Graceway Pharmaceuticals, LLC
- Tennessee Clinical Research Center
For direct contact, visit the study record on ClinicalTrials.gov .